| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 9 Feb 2026 | 2 Feb 2026 |
| Quarterly Results Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider and approve In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this to inform you that a meeting of the Board of Directors of the Company will be held on Monday, February 09, 2026, inter alia to Consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025. This is to further inform you that in accordance with the Companys Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in securities of the Company by Designated Persons and their immediate relatives is closed from January 01, 2026, till 48 hours after declaration of Unaudited Financial Results on February 09, 2026. Kindly take the above information on your records. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Monday, February 09, 2026, inter-alia considered and approved the following: Unaudited Financial Results, Change in Directorate - Appointment/ Re-appointment of Independent Directors, Reconstitution of Committees of the Board. The details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith. The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 05.00 p.m. Kindly take the above information on your records. (As per BSE Announcement dated on: 09.02.2026) | ||
| Board Meeting | 12 Nov 2025 | 5 Nov 2025 |
| Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday November 12 2025 inter alia to Consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2025. This is to further inform you that in accordance with the Companys Code of Conduct for Prevention of Insider Trading the Trading Window for dealing in securities of the Company by Designated Persons and their immediate relatives is closed from October 1 2025 till 48 hours after declaration of Unaudited Financial Results on November 12 2025. Kindly take the above information on your records. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Wednesday, November 12, 2025, inter-alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025. A copy of the same is enclosed along with the Limited Review Report of the Statutory Auditors thereon in terms of SEBI (LODR) Regulations, 2015. The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 03.30 p.m. Kindly take the above information on your records. Unaudited Financial Results for the Quarter and Half year ended September 30,2025 are enclosed herewith. Kindly take the same on record. (As Per BSE Announcement Dated on:12.11.2025) | ||
| Board Meeting | 13 Aug 2025 | 6 Aug 2025 |
| Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday August 13 2025 inter alia to Consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30 2025. This is to further inform you that in accordance with the Companys Code of Conduct for Prevention of Insider Trading the Trading Window for dealing in the securities of the Company by Designated Persons and their immediate relatives is closed from July 1 2025 till 48 hours after declaration of Unaudited Financial Results on August 13 2025. Kindly take the above information on your records. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Wednesday, August 13, 2025, inter-alia considered and approved the following: 1. Unaudited Financial Results: The Unaudited Financial Results for the Quarter ended June 30, 2025. A copy of the same is enclosed along with the Limited Review Report of the Statutory Auditors thereon in terms of SEBI (LODR) Regulations, 2015. 2. Approved revision/change in the following Policy/Code: ? Nomination and Remuneration Policy. ? Policy on Determination of Materiality of Events ? Code of Conduct to Regulate, Monitor and Report on Trading in Securities by Insiders. The Meeting of the Board of Directors of the Company commenced at 03:30 p.m. and concluded at 04.10 p.m. Kindly take the above information on your records. (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 27 May 2025 | 20 May 2025 |
| Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2025 inter alia to consider and approve In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday May 27 2025 inter alia to: 1. Consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31 2025. 2. Recommend dividend if any on the Equity Shares of the Company for the financial year ended March 31 2025. This is to further inform you that in accordance with the Companys Code of Conduct for Prevention of Insider Trading the Trading Window for dealing in the securities of the Company by Designated Persons and their immediate relatives is closed from April 1 2025 till 48 hours after declaration of Audited Financial Results on May 27 2025. Kindly take the above information on your records. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Tuesday, May 27, 2025, inter-alia considered and approved the following: 1. Audited Financial Results 2. Dividend 3. Appointment of Secretarial Auditors The Meeting of the Board of Directors of the Company commenced at 03:30 p.m. and concluded at 04.10 p.m. Kindly take the above information on your records. (As Per BSE Announcement Dated :27.05.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
